Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia

We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenström macroglobulinemia (WM). WM patients with less than 2 prior therapies were eligible. Intended therapy consisted of 6 cycles (25 mg/m(2) per day for 5 days) of fludarabine and 8 infus...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Treon, Steven P., Branagan, Andrew R., Ioakimidis, Leukothea, Soumerai, Jacob D., Patterson, Christopher J., Turnbull, Barry, Wasi, Parveen, Emmanouilides, Christos, Frankel, Stanley R., Lister, Andrew, Morel, Pierre, Matous, Jeffrey, Gregory, Stephanie A., Kimby, Eva
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2009
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2670786/
https://ncbi.nlm.nih.gov/pubmed/19015393
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-09-177329
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares